CTOs on the Move

Phosplatin Therapeutics

www.phosplatin.com

 
Phosplatin Therapeutics is a private, clinical stage biopharmaceutical company founded in 2010, and funded by private investors and family investment offices in the U.S., Europe and Asia.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

Phosplatin Therapeutics raised $16M on 10/31/2018
Phosplatin Therapeutics raised $18.4M on 08/26/2020

Similar Companies

Organogenesis

Organogenesis Inc. is a Canton, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

NatureWorks

NatureWorks LLC is a Minnetonka, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Frontier Medicines

Frontier Medicines is a pre-clinical stage biopharmaceutical company developing breakthrough medicines that redefine the course of debilitating diseases. According to the American Cancer Society, 1,762,000 new cancer cases and 607,000 deaths from cancer are expected to occur in the US in 2019. Our focus is developing treatments against important cancer-causing proteins that the biopharma industry hasn`t found a way to treat (or “drug”) with pharmaceutical interventions. After decades of research, this has become one of the most critical challenges in addressing human disease and advancing oncology therapy --central to the research at Frontier Medicines. Frontier Medicines is using chemoproteomics – an innovative approach to chemically interrogate proteins in living systems – to discover and pharmacologically target new binding pockets (or “hotspots”) on proteins, making them accessible to small-molecule drug discovery and development. The company`s proprietary chemoproteomics platform also integrates advanced computational approaches and machine learning to further accelerate the path to drug discovery.

Astra Zeneca Neuroscience

Astra Zeneca Neuroscience is a Cambridge, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Lumos Pharma

Lumos Pharma, based in Austin, Texas, is an early stage biotechnology company created to develop and commercialize a novel treatment for the rare disease Creatine Transporter Deficiency. Lumos Pharma is the exclusive licensee of technology and discoveries made in laboratories at the University of Cincinnati and has partnered with Key Opinion Leaders in the field and the United States National Institutes of Health to ensure success in developing a treatment for Creatine Transporter Deficiency.